, Volume 30, Issue 11, pp 1067–1084 | Cite as

The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes

A New Zealand Evaluation
  • Laura PanattoniEmail author
  • Paul M. Brown
  • Braden Te Ao
  • Mark Webster
  • Patrick Gladding
Original Research Article


Background: A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel. The frequency of the *2 allele varies by ethnicity and the Maoris, Asians and Pacific Islanders of New Zealand have a relatively high incidence.

Objective: Our objective was to evaluate, from a New Zealand health system perspective, the cost effectiveness of treating all ACS patients with generic clopidogrel compared with prasugrel, and also compared with the genetically guided strategy that *2 allele carriers receive prasugrel and non-carriers receive clopidogrel.

Methods: A decision-tree model consisting of five health states (myocardial infarction, stroke, bleeding, stent thrombosis and cardiovascular death) was developed. Clinical outcome data (two TRITON-TIMI 38 genetic sub-studies) comparing clopidogrel and prasugrel for both *2 allele carriers and non-carriers were combined with the prevalence of the heterozygosity for the *2 allele in New Zealand Europeans (15%), Maoris (24%), Asians (29%) and Pacific Islanders (45%) to determine the predicted adverse event rate for the New Zealand population. National hospital diagnosis-related group (DRG) discharge codes were used to determine alternative adverse event rates, along with the costs of hospitalizations during the 15 months after patients presented with an ACS. The primary outcome measure was the incremental cost per QALY (calculated using literature-reported weights). Monte Carlo simulations and alternative scenario analysis based on both clinical trial and national hospital incidence were used. Additional analysis considered the overall TRITON-TIMI 38 rates. Costs (in New Zealand dollars [$NZ], year 2009 values) and benefits were discounted at 3% per annum.

Results: Actual hospital-based adverse event rates were higher than those reported in the TRITON-TIMI 38 randomized controlled trial and the genetic sub-studies, especially for myocardial infarction and cardiovascular death, and for Maoris and Pacific Islanders. For both sources of adverse event rates, treating the population with prasugrel was associated with worse outcomes (QALYs) than clopidogrel. However, prasugrel became cost effective ($NZ31 751/QALY) when the overall TRITON-TIMI 38 rates were used. A genetic test to guide the selected use of prasugrel was cost effective ($NZ8702/QALY versus $NZ24617/QALY) for hospital and clinical trial incidence, respectively. Based on the hospital rates, the genetically guided strategy was especially cost effective for Maoris ($NZ7312/QALY) and Pacific Islanders ($NZ7041/QALY). These results were robust to the sensitivity analysis, except the genetically guided strategy under the 15-month clinical trial event rate scenario ($NZ168 748/QALY) did not remain cost effective under a $NZ50 000 threshold.

Conclusions: Use of a genetic test to guide thienopyridine treatment in patients with ACS is a potentially cost-effective treatment strategy, especially for Maoris and Pacific Islanders. This treatment strategy also has the potential to reduce ethnic health disparities that exist in New Zealand. However, the results comparing clopidogrel and prasugrel are sensitive to whether the genetic sub-studies or the overall TRITON-TIMI 38 rates are used. While the national hospital event rates may be more appropriate for the New Zealand population, many assumptions are required when they are used to adjust the genetic sub-studies rates.


Acute Coronary Syndrome Clopidogrel Stent Thrombosis Pacific Islander Prasugrel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The funding for this study was provided by the Auckland District Health Board A-Plus Trust, an organization of the New Zealand national public health system. This work was funded through a charitable grant and the sponsor played no role in any part of this study. Dr Patrick Gladding is the founder of and shareholder in the non-profit translational research company, Theranostics Laboratory (NZ) Ltd. Dr Patrick Gladding and Dr Mark Webster have an issued USPTO (US Patent and Trademark Office) patent 12/950,617 on treatment strategies related to clopidogrel pharmacogenetics. Dr Laura Panattoni, Dr Paul Brown and Braden Te Ao have no conflicts to disclose.

The authors would also like to acknowledge Dr Lifeng Zhou at the Waitemata District Health Board for his invaluable assistance in medical coding.

Laura Panattoni is now employed by the Department of Health Policy Research, Palo Alto Medical Foundation Research Institute, Palo Alto, CA, USA. Braden Te Ao is currently employed by Auckland University of Technology, Auckland, New Zealand. Patrick Gladding is currently employed by North Shore Hospital, Auckland, New Zealand.

Laura Panattoni designed the research methodology, conducted the literature search for model parameters, estimated the national hospital adverse event rates and costs, conducted the cost-effectiveness calculation and participated in manuscript writing. Paul Brown designed the research methodology and participated in manuscript writing. Braden Te Ao conducted the literature search for model parameters and the cost-effectiveness calculation. Mark Webster designed the research methodology, conducted the literature search for model parameters and participated in manuscript writing. Patrick Gladding designed the research methodology, conducted the literature search for model parameters, participated in manuscript writing and won the grant. Laura Panattoni is the guarantor of the overall content of this article.


  1. 1.
    Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527–33.PubMedCrossRefGoogle Scholar
  2. 2.
    Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108 (14): 1682–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 338: 2001–15.CrossRefGoogle Scholar
  4. 4.
    Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel — thrombolysis in myocardial infarction TRI-TON-TIMI 38. Circulation 2010; 121: 71–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354–62.PubMedCrossRefGoogle Scholar
  6. 6.
    Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553–60.PubMedCrossRefGoogle Scholar
  7. 7.
    US FDA. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug [online]. Available from URL: [Accessed 2010 Apr 5].
  8. 8.
    Lea RA, Roberts RL, Green MR, et al. Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Maori. N Z Med J 2008; 121 (1272): 33–7.PubMedGoogle Scholar
  9. 9.
    Robarge J, Fletcher R, Nguyen A, et al. Gene: CYP2C19 [online]. Available from URL: [Accessed 2010 Jan 20].
  10. 10.
    New Zealand Ministry of Health. National Minimum Dataset: hospital events [online]. Available from URL: [Accessed 2012 Aug 4].
  11. 11.
    Riddell T, North D. Socioeconomic and ethnic inequalities in cardiovascular disease: technical report to medical and Allied Health Professionals [report no. 80]. Auckland: National Heart Foundation, 2003.Google Scholar
  12. 12.
    Pharmaceutical Management Agency. New Zealand pharmaceutical schedule. Wellington: PHARMAC, 2006.Google Scholar
  13. 13.
    New Zealand Health Information Service. New Zealand casemix framework for publicly funded hospitals including WIESNZ08 methodology and casemix purchase unit allocation for the 2008/09 financial year [online]. Available from URL: [Accessed 2012 Aug 4].
  14. 14.
    Pharmaceutical Management Agency. Section H of the Pharmaceutical Schedule (hospital pharmaceuticals), effective 1 Dec 2009 [online]. Available from URL: [Accessed 2012 Aug4].
  15. 15.
    Te Ao BJ, Brown PM, Feigin VL, et al. Are stroke units cost effective? Evidence from a New Zealand stroke incidence and population-based study. Int J Stroke. Epub 2011 Oct 20.Google Scholar
  16. 16.
    Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes study: initial catalog of health-state quality factors. Med Dec Making 1993; 13: 89–102.CrossRefGoogle Scholar
  17. 17.
    Lord SJ, Allen F, Atherton JJ, et al. A systematic review and economic analysis of drug-eluting coronary stent available in Australia. Med J Australia 2005; 183 (9): 464–71.PubMedGoogle Scholar
  18. 18.
    Statistics New Zealand. Complete period life tables: 2005–2007 [online]. Available from URL: [Accessed 2010 Jan 10].
  19. 19.
    Karnon J, Holmes M, Williams R, et al. A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. Int J Cardiol 2008; 140 (3): 315–22.PubMedCrossRefGoogle Scholar
  20. 20.
    US FDA. Effient label [online]. Available from URL: [Accessed 2012 Aug 4].
  21. 21.
    Sorich MJ, Vitry A, Ward MD, et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010; 8: 1678–84.PubMedCrossRefGoogle Scholar
  22. 22.
    Congressional Budget Office. Research on the comparative effectiveness of medical treatments. Washington, DC: Congressional Budget Office, 2007.Google Scholar
  23. 23.
    Berger CJ, Joanne MM, Evans JC, et al. Prognosis after first myocardial infarction: comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA 1992; 268 (12): 1545–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Fox KAA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006; 333 (7578): 1091.PubMedCrossRefGoogle Scholar
  25. 25.
    Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010 Feb 2; 121 (4): 512–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol 2010; 55: 2804–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Ray T. Vanderbilt Medical Center initiates Plavix PGx testing for all cardiac catheterization patients. Pharmacogenomics Reporter 2010 Oct 6 [online]. Available from URL: [Accessed 2011 Jan 15].
  28. 28.
    Holmes D, Dehmer G, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “Boxed Warning”. J Am Coll Cardiol 2010; 56: 321–41.PubMedCrossRefGoogle Scholar
  29. 29.
    Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502.PubMedCrossRefGoogle Scholar
  30. 30.
    Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19): 2411–20.PubMedCrossRefGoogle Scholar
  31. 31.
    Park SJ, Park DW, Kim YH, et al. Duration of dual anti-platelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374–82.PubMedCrossRefGoogle Scholar
  32. 32.
    Hsu HL, Woad KJ, Woodfield DG, et al. A high incidence of polymorphic CYP2C19 variants in archival blood samples from Papua New Guinea. Hum Genomics 2008; 3 (1): 17–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics 1996; 6 (3): 265–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Laura Panattoni
    • 1
    • 7
    Email author
  • Paul M. Brown
    • 1
    • 2
  • Braden Te Ao
    • 1
  • Mark Webster
    • 3
    • 4
  • Patrick Gladding
    • 3
    • 5
    • 6
  1. 1.School of Population HealthUniversity of AucklandAucklandNew Zealand
  2. 2.School of Social Sciences, Humanities and ArtsUniversity of CaliforniaMercedUSA
  3. 3.School of MedicineUniversity of AucklandAucklandNew Zealand
  4. 4.Green Lane Cardiovascular ServiceAuckland City HospitalAucklandNew Zealand
  5. 5.Cleveland Clinic FoundationClevelandUSA
  6. 6.Theranostics LaboratoryClevelandUSA
  7. 7.Department of Health Policy ResearchPalo Alto Medical Foundation Research InstituteMountain ViewUSA

Personalised recommendations